Biologists are from Mars, chemists are from Venus?

“Plays well with others.” That popular phrase on a T-shirt is being taken to a whole new level in higher education these days, as experts in a variety of fields increasingly must work together to address some of society's biggest challenges, from a warming planet to cancer.

But how do scientists from different disciplines and institutions collaborate? How do they work together to incorporate the distinct perspectives, languages and research styles of their fields?

“When scientists from different disciplines say 'We work together,' we want to know what that means,” says Steve Fifield, associate policy scientist at the University of Delaware.

Fifield, who is affiliated with the Delaware Education Research and Development Center at UD, is leading research to uncover how scientists from different disciplines form working relationships. The two-year project is funded by a $197,300 grant from the National Science Foundation's Innovation and Organizational Sciences program.

The findings will shed light on scientific collaboration--a process about which little is known, but much is expected.

“Agencies such as the National Science Foundation have deemed large-scale interdisciplinary research projects critical to U.S. innovation and competitiveness,” Fifield notes. “Yet there have been few studies of how scientists actually bridge disciplinary boundaries. There's no 'how-to' for it--at least not yet,” he says, smiling.

Fifield's research team includes co-investigators Regina Smardon, a sociologist at the University of Virginia, and Karl Steiner, associate director of the Delaware Biotechnology Institute, along with postdoctoral researcher Katherine McGurn Centellas and graduate research assistant Jennifer Koester.

Two emerging research centers at UD are the focus of the study. The Center for Translational Cancer Research involves individuals from UD, Alfred I. duPont Hospital for Children/Nemours, Christiana Care Health System/Helen F. Graham Cancer Center, and the Delaware Biotechnology Institute. The center, under the direction of Mary C. Farach-Carson, professor of biological sciences, seeks to establish a pipeline for developing translational cancer researchers and clinicians, spanning the undergraduate to postgraduate levels, and to build teams of clinicians, biologists and engineers, chemists and computer scientists to attack cancer-related problems.

The Center for Critical Zone Research, led by Donald Sparks, the S. Hallock du Pont Chair of Plant and Soil Sciences, aims to develop a world-class, leading-edge research capability focusing on the Earth's “critical zone”--the life-sustaining environment from the treetops to the groundwater where complex interactions of rock, soil, water, air and living organisms occur. Interfacial chemistry, bionanotechnology, and environmental genomics are the center's primary research areas.

The project team has been busy interviewing researchers affiliated with the centers and observing them in labs, seminars, even tumor clinics, as well as social settings, such as monthly get-togethers at Grotto's Pizza.

“We're studying 'participation customs'--how groups of people interact,” Centellas says. An anthropologist with a background in biology, she also has significant international experience, studying the organizational structure and dynamics of research centers in Bolivia.

“Scientists come trained in a particular way according to their discipline,” she notes. “Each group comes with a different vocabulary. How does one group learn to communicate with another? How do people discuss problems and form collegial relationships? How does work get assigned--is it by expertise, by technical facility, by the availability of a grad student? We're getting into the nuts and bolts of people coming together,” she says.

Koester, a master's student in sociology, is observing researchers to see if their collaboration is static or dynamic.

“Are people actively involved in communicating with one another, dividing up tasks, or is it done mostly at a distance, or without much interaction?” she says. “That gives us a lot of insight into how transformative the process is.”

Koester eventually wants to become a professor herself, leading research projects and teaching students in social science.

Although the project only began last fall, the team already has several preliminary findings and will present their results at the American Sociological Society's annual meeting in August.

“We've discovered that individuals can find themselves narrowing back to a niche specialization when doing collaborative research,” Fifield says. “Thus, interdisciplinary research may tend to move people back to their core expertise.”

The scientists also have noticed differences in culture between academics doing cancer research versus clinicians (medical doctors) who want to pursue cancer research in academia. Some meetings begin at Christiana Hospital at 7 a.m., which is before the workday starts for many university researchers.

“It's a time-use issue--in how you think about what an hour is worth,” Centellas says. “People may need to modify certain behaviors to become part of a group.”

By the end of the two-year project, the team will better understand the kinds of choices and strategies that help researchers to collaborate--how people manage to achieve it, and what gets in the way. The research may not result in a “how-to” list, Fifield says, but the team will be able to offer take-away messages and tips.

“Right now, the processes of interdisciplinary research get black-boxed. They remain a bit of a mystery. We may be able to unpack that a bit,” he notes.

Source: University of Delaware

Related stories:

Parsing the genome of a deadly brain tumor
The most comprehensive to-date genomic analysis of a cancer – the deadly brain tumor glioblastoma multiforme – shows previously unrecognized changes in genes and provides an overall view of the missteps in the pathways that govern the growth and behavior of cells, said members of The Cancer Genome Atlas Research Network in a report that appears online today in the journal Nature.
FDA posts list of potential problem drugs
(AP) -- The government on Friday began posting a list of prescription drugs under investigation for potential safety problems, in an effort to better inform doctors and patients.
Creating lung cancer risk models for specific populations refines prediction
Lung cancer risk prediction models are enhanced by taking into account risk factors by race and by measuring DNA repair capacity, according to research teams led by epidemiologists at The University of Texas M. D. Anderson Cancer Center in two complementary papers appearing in the September issue of Cancer Prevention Research.
1 step back ... 2 steps forward
Women with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposium may change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.
Studies spot numerous undiscovered gene alterations in pancreatic and brain cancers
HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. Some of these genetic changes were previously unknown and could provide new leads for improved diagnosis and therapy for these devastating cancers.
Potential remedy for the 'mental fog' in cancer patients
Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University (WVU), researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce. The WVU researchers' study has just been published in the September issue of the Springer journal Metabolic Brain Disease.
International team reveals first prognosticator of survival in aggressive cancer
The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS), according to an international collaboration of researchers, including scientists at the Sbarro Institute for Cancer Research and Molecular Medicine at the College of Science and Technology at Temple University in Philadelphia, PA, the Department of Human Pathology and Oncology, University of Siena and the Center of Oncological Research of Mercogliano (CROM) in Avellino, Italy.
Study: New way to spot breast cancer shows promise
(AP) -- A radioactive tracer that "lights up" cancer hiding inside dense breasts showed promise in its first big test against mammograms, revealing more tumors and giving fewer false alarms, doctors reported Wednesday. The experimental method - molecular breast imaging, or MBI - would not replace mammograms for women at average risk of the disease.

News discussion:

General Science news